# US Food and Drug Administration Inspection Analysis

Analysis of US FDA inspection classifications from October 2008 through March 2015

##Questions to Answer
The purpose of analyzing data is to learn the answer to a question(s) and/or to prove or disprove a theory. This analysis seeks to answer the questions below.

- What is the annual summary of ratings for each center, area and district?
- Over the years, how do districts compare for each center and project area?
- How many rating types were given annually by district? How does this look on the map?
- Were multiple inspections performed for the same company? If so, were the OAI findings reinspected? What was the result?
- Do more inspections occur closer to MD where the centers are located?

###General Information and Definitions
[FDA Centers](http://www.fda.gov/RegulatoryInformation/Guidances/ucm125789.htm)
- Center for Biologics Evaluation and Research (CBER)
- Center for Drug Evaluation and Research (CDER)
- Center for Devices and Radiological Health (CDRH)
- Center for Vetinary Medicine (CVM)
- Center for Food Safety and Applied Nutrition (CFSAN)

[Inspection Classifications](http://www.fda.gov/downloads/AboutFDA/Transparency/PublicDisclosure/GlossaryofAcronymsandAbbreviations/UCM212061.pdf)
- No Action Indicated (NAI): no objectionable condition or practices were found
- Volunatry Action Indicated (VAI): objectionable conditions or practices were found that do not meet the threshold of regulatory significance
- Official Action Indicated (OAI): objectionable conditions or practices were found and regulatory action is warranted


Data downloaded from [FDA site](http://www.fda.gov/ICECI/Inspections/ucm222557.htm) 01 November 2015
